Model-informed dose optimization for prophylactic piperacillin-tazobactam in perioperative pediatric critically ill

Wen Rui Tan1,2, Kei Irie2, Carter McIntire3

  • 1Department of Pharmacology and System Physiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Insights

Optimizing piperacillin/tazobactam (PTZ) dosing for critically ill pediatric patients during surgery is crucial. New regimens, including lower intermittent doses or continuous infusions, may improve safety and efficacy, addressing concerns about kidney toxicity and dosing practicality.

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Pediatric Critical Care

Background:

  • Piperacillin/tazobactam (PTZ) is a common perioperative antibiotic prophylaxis in critically ill children.
  • Current pediatric intraoperative dosing guidelines for PTZ may pose risks of nephrotoxicity and present practical challenges in clinical settings.

Purpose of the Study:

  • To optimize piperacillin/tazobactam (PTZ) dosing regimens in pediatric intraoperative patients using population pharmacokinetic (PK) modeling.
  • To evaluate alternative dosing strategies that enhance efficacy and reduce potential adverse events.

Main Methods:

  • Population pharmacokinetic (PK) modeling and simulation were employed using piperacillin (PIP) plasma concentration data from 34 pediatric patients.
  • A two-compartment model was developed, identifying creatinine clearance as a covariate on clearance and incorporating inter-occasion variability.

Main Results:

  • Simulations demonstrated that lower intermittent doses (6-15 mg/kg every 2 hours) or continuous infusions (1.0-2.75 mg/kg/h) achieve target PIP concentrations above 1x MIC for 100% of the dosing interval.
  • Higher intermittent doses (25-55 mg/kg every 2 hours) or continuous infusions (3.25-9.25 mg/kg/h) were derived to achieve 100% fT >4× MIC.

Conclusions:

  • Model-informed simulations suggest that optimized PTZ dosing, including lower intermittent doses and continuous infusions, are clinically viable.
  • These alternative strategies may effectively address current clinical challenges associated with intraoperative PTZ dosing in pediatric patients.